

# Jason C Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3211837/publications.pdf>

Version: 2024-02-01

38  
papers

2,405  
citations

331670

21  
h-index

330143

37  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3356  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>FGFR2::TACC2</i> fusion as a novel <i>KIT</i> -independent mechanism of targeted therapy failure in a multidrug-resistant gastrointestinal stromal tumor. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 412-419.	2.8	4
2	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 515-528.	2.8	12
3	Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset. <i>Clinical Cancer Research</i> , 2022, 28, 4702-4713.	7.0	25
4	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 253-263.	2.8	20
5	<i>MET</i> Exon 14-altered Lung Cancers and MET Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 799-806.	7.0	35
6	Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. <i>Cell Reports</i> , 2021, 34, 108707.	6.4	16
7	Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?. <i>Lung Cancer</i> , 2021, 153, 158-164.	2.0	4
8	Rapid EGFR Mutation Detection Using the Idylla Platform. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 310-322.	2.8	19
9	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 4066-4076.	7.0	45
10	Multiomic Analysis of Lung Tumors Defines Pathways Activated in Neuroendocrine Transformation. <i>Cancer Discovery</i> , 2021, 11, 3028-3047.	9.4	66
11	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	12.8	68
12	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1188-1199.	1.1	23
13	Spectrum of <i>BRAF</i> Mutations and Gene Rearrangements in Ovarian Serous Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1480-1492.	3.0	8
14	Bronchiolar Adenoma/Pulmonary Ciliated Muconodular Papillary Tumor. <i>American Journal of Clinical Pathology</i> , 2021, 155, 832-844.	0.7	20
15	Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. <i>Journal of Hematology and Oncology</i> , 2021, 14, 170.	17.0	26
16	Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2020, 21, e25-e29.	2.6	1
17	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. <i>Journal of Thoracic Oncology</i> , 2020, 15, 231-247.	1.1	172
18	SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1823-1835.	1.1	234

#	ARTICLE	IF	CITATIONS
19	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	7.0	133
20	CNS Metastases in Patients With MET Exon 14-Altered Lung Cancers and Outcomes With Crizotinib. <i>JCO Precision Oncology</i> , 2020, 4, 871-876.	3.0	14
21	MET-dependent solid tumours – molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	27.6	165
22	Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. <i>Histopathology</i> , 2020, 77, 915-925.	2.9	92
23	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. <i>Modern Pathology</i> , 2020, 33, 2244-2255.	5.5	23
24	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2654-2663.	7.0	230
25	RUNX2 (6p21.1) amplification in osteosarcoma. <i>Human Pathology</i> , 2019, 94, 23-28.	2.0	13
26	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. <i>Clinical Cancer Research</i> , 2019, 25, 7113-7125.	7.0	69
27	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. <i>Journal of Thoracic Oncology</i> , 2019, 14, 825-834.	1.1	62
28	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. <i>Clinical Cancer Research</i> , 2019, 25, 4712-4722.	7.0	292
29	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. <i>Modern Pathology</i> , 2019, 32, 1106-1122.	5.5	58
30	JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. <i>Human Pathology</i> , 2019, 88, 87-91.	2.0	20
31	Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 307-317.	2.8	19
32	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 87-98.	1.1	153
33	Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 9028-9028.	1.6	22
34	Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence. <i>Blood</i> , 2019, 134, 3380-3380.	1.4	0
35	Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. <i>Cancer Discovery</i> , 2018, 8, 686-695.	9.4	149
36	Bronchiolar Adenoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1010-1026.	3.7	91

#	ARTICLE	IF	CITATIONS
37	Type A thymoma presenting with bone metastasis. <i>Histopathology</i> , 2018, 73, 701-703.	2.9	1
38	Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e81-e83.	2.6	1